Arizona Cancer Center member publishes books on prostate cancer

[Source: Donna Breckenridge, Arizona Cancer Center] -- Richard J. Ablin, PhD, a member of the Arizona Cancer Center’s Biology and Genetics Program, has published a new book, Metastasis of Prostate Cancer, available from Springer Press. The book provides an innovative look at prostate cancer with specific focus on metastasis (secondary malignant growths from a primary site of cancer). Dr. Ablin’s book is especially useful for researchers and physicians interested in the origins and spread of prostate cancer, and in the mechanisms of metastasis of other forms of cancer. He is a well-known innovator in the field of prostate cancer research and is the discoverer of prostate-specific antigen (PSA). The book is Dr. Ablin’s fourth and is co-edited by Malcolm D. Mason of Wales. Metastasis of Prostate Cancer contributes to the efforts of laboratory researchers to translate their discoveries into clinical applications, enabling efforts in the laboratory to make a visible difference in the lives of patients for whom the research is meant. Its scope ranges from basic research at the molecular biology level to treatments for prostate cancer patients. Curative approaches are also presented, ranging from conventional drug design to immunogene therapy.

Dr. Ablin earned a doctoral degree in microbiology from the State University of New York at Buffalo and was also trained as a United States Public Health Service Postdoctoral Fellow. From his undergraduate alma mater, Lake Forest College, he received the degree of D.Sc., honoris causa. In 1997, for his discovery of PSA in 1970, Dr. Ablin was a nominee for the Lasker Award. Included in the First Edition of Who’s Who in Emerging Leaders of America in 1987, Dr. Ablin was an early investigator of the immunobiological aspects of the development and progression of cancer and a pioneer in the field of cryosurgery (the application of intense cold for the destruction of unwanted tissue) and the concept of “cryoimmunotherapy” for the treatment of cancer. He is a member of numerous professional societies and serves on the editorial board of several medical journals.